Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments ...
The first-ever oral version of semaglutide for weight loss just hit the market. Here’s what you need to know. For years, ...
Stocktwits on MSN
Novo Nordisk offers oral Wegovy pill at $149 a month following FDA’s approval in December: Retail tells shorts 'it's time to give up'
However, the price of the 4 mg dose will rise to $199 a month from April 15, 2026, the company said. ・There are no ...
The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...
When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...
Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...
--Down 48.34% year-to-date; on pace for worst year since 1984, when it fell 57.59% --Down 69.75% from its all-time closing high of $146.91 on June 25, 2024 --Down 57.50% from 52 weeks ago (Nov. 25, ...
Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Pfizer has won the ...
Novo Nordisk, Eli Lilly agree to lower GLP-1 drug prices in US Analysts see short-term revenue hit, long-term volume boost FDA weighs expedited Novo obesity pill review, Lilly yet to submit The deal ...
Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 ...
As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback